Anovulation is a not a disease but a sign, in much the same way that polycystic ovaries are the manifestation of a much larger disease process. The ovulation process occurs in the hypothalamic-pituitary-ovarian (HPO) axis and is orchestrated by a neuroendocrine cascade terminating in the ovaries. Any alteration results in a failure to release a mature ovum, leading to anovulatory cycles. Thus, treatment of anovulation involves a multi-tier management and usually complex.
The drug Clomifene is a selective estrogen receptor modulator (SERM) of the triphenylethylene group that has become the most widely prescribed drug since 1960 for ovulation induction. The present article gives a brief overview of the use, dosage, adverse effect and off-label use of this drug. This drug is listed in WHO Model List of Essential Medicines (most efficacious, cost-effective, safe medicines that are a minimum…
